About Us
Welcome to TORC, your trusted partner in outcomes assessment for Thyroid Eye Disease (TED). With over 15 years of dedicated research led by Dr. Shoaib Ugradar, our outcomes assessment process stands as a testament to unrivaled expertise. Dr. Ugradar's extensive research, spanning over 60 publications, has unearthed critical parameters for understanding and measuring TED progression and therapeutic outcomes.
TED, also known as Graves' Ophthalmopathy, presents unique challenges as a complex autoimmune disorder affecting the eyes and surrounding tissues. Accurate measurement is paramount in identifying effective treatments within clinical trials. At TORC, we're committed to propelling thyroid eye disease research through our innovative imaging data solutions.
Our
Mission
Our mission is to provide researchers, clinicians, and pharmaceutical companies with the highest quality thyroid eye disease imaging data to facilitate groundbreaking research and improve patient care.
We understand the critical importance of accurate data for diagnosis, treatment, and scientific discovery. As a trusted partner in the field, we aim to accelerate progress in the study of TED.
Our
Values
01
Advanced
At TORC, advancement is more than a goal—it's a commitment. We continuously harness cutting-edge technologies and methodologies to ensure our solutions stand at the forefront of clinical research, driving progress and innovation in every endeavor.
03
Secure
We pride ourselves on our established track record and unwavering commitment to reliability. With years of seasoned experience, we employ rigorous measures and best practices to ensure data integrity and confidentiality.
02
Exact
Precision is the cornerstone of our approach. TORC's dedication to exactness ensures that every data point, solution, and outcome is delivered with unparalleled accuracy. We believe that clarity in detail lays the foundation for impactful results.
04
Human-Centric
Behind every project, data point, and solution, lies the human element. TORC's human-centric approach prioritizes understanding and collaboration. We believe in crafting solutions that resonate, ensuring research outcomes are both impactful and personal.
05
Flexible
In the dynamic realm of clinical research, adaptability is key. TORC prides itself on its flexible approach, tailoring solutions to meet evolving needs and challenges. Our agility ensures we remain responsive, proactive, and always aligned with our partners' objectives.
Our
Solutions
Clinical Activity Scores and exophthalmometer measurements have been shown to be unreliable, varying from clinician to clinician. TORC moves beyond these barriers by using MRI or CT scans to create three-dimensional imaging of the orbits, providing next-level accuracy.
In addition, we've collaborated on an intuitive image repository platform tailored for clinical trials, ensuring compliance with global privacy and security regulations. This streamlined solution simplifies the management of imaging data, empowering clinical research sites to achieve success with ease.
Leadership Team
Founded by Dr. Shoaib Ugradar, TORC's team boasts an extensive twenty-year commitment to advancing Thyroid Eye Disease (TED) research. Together, TORC founders were among the pioneering groups to recognize the therapeutic potential of IGF-1R therapy for TED.
Today, TORC's proprietary technology is integral to several significant trials in collaboration with leading organizations such as Horizon Therapeutics, Viridian Therapeutics, and Valenza Bio. Our methodologies and findings have been recognized in more than 20 peer-reviewed publications spanning the fields of ophthalmology and endocrinology, reflecting our dedication to advancing scientific knowledge and study.
CEO
Dr. Shoaib Ugradar, MD
Dr. Ugradar originally trained as an internist in London, England, gaining the highest marks on the board exams. He later went on to train in ophthalmology at the renowned Moorfields Eye Hospital, London, United Kingdom, where he was awarded a gold medal for research. Following his training in the UK, Dr. Ugradar completed a research fellowship at UCLA with Dr. Robert Alan Goldberg, MD (the Bert O. Levy Endowed Chair in Orbital and Ophthalmic Plastic Disease). This work led to the invention of novel devices that have gained patents in the United States. Dr. Ugradar sees comprehensive and oculoplastic patients within the UCLA Stein Eye Institute in various locations. Dr. Ugradar has published multiple papers and book chapters in the field of oculoplastics, and he is a reviewer for numerous journals. His laboratory research focuses on thyroid eye disease, artificial intelligence, and cosmetics.
Dr Ugradar's research has led to awards from the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) for research in 2020 and 2021.
IT and Infrastructure
Thomas Summerfelt, PhD
Dr. Summerfelt has over 25 years of experience in clinical research. He completed his PhD at Vanderbilt University and was awarded both pre- and post-doctoral fellowships from the US National Institutes of Health in health services research. He has held faculty positions in the School of Medicine at Vanderbilt University, College of Human Medicine at Michigan State University, and the School of Medicine at the University of Chicago. In addition, he was the lead research administrator for a large health care system in Illinois and Wisconsin (research staff of 75 FTE, 700 IRB-approved studies at any given time, and over 1,000 investigators). Finally, Dr. Summerfelt has international experience in sharing and protecting clinical research data in the US, China, Canada, Europe, and Japan.
Sponsors
